TABLE 4.
The Risk of Strong Opioid and Neuropathic Medication Use for the Explanted Group and the Trial Group Compared With the Permanent Group
| Permanent (n = 19) | Explanted (n = 8) | Trial only (n = 8) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | MME (mean ± SD) | n (%) | MME (mean ± SD) | OR (95% CI) | P c | n (%) | MME (mean ± SD) | OR (95% CI) | P c | |
| Strong opioid use before SCS (18-0 mo)a | 4 (21) | 53 ± 150 | 2 (25) | 27 ± 72 | 1.3 (0.18-8.7) | .82 | 3 (38) | 71 ± 200 | 2.3 (0.37-14) | .38 |
| Strong opioid use after SCS (6-24 mo)b | 8 (42) | 120 ± 240 | 5 (63) | 57 ± 66 | 2.3 (0.42-13) | .34 | 3 (38) | 66 ± 180 | 0.83 (0.15-4.5) | .82 |
| DDD (mean ± SD) | DDD (mean ± SD) | DDD (mean ± SD) | ||||||||
| Neuropathic medication use before SCS (18-0 mo)a | 16 (84) | 0.52 ± 0.57 | 6 (75) | 1.4 ± 0.90 | 0.6 (0.07-4.2) | .58 | 7 (88) | 0.73 ± 0.61 | 1.3 (0.12-15) | .83 |
| Neuropathic medication use after SCS (6-24 mo)b | 10 (53) | 0.82 ± 0.48 | 5 (63) | 1.2 ± 1.2 | 1.5 (0.28-8.1) | .64 | 5 (63) | 1.5 ± 0.68 | 1.5 (0.28-8.1) | .64 |
MME = mean daily opioid dose purchased in morphine milligram equivalent during an 18-mo period related to the SCS implantation date; DDD = mean daily neuropathic medication purchased in defined daily dose during an 18-mo period related to the SCS implantation date.
aAt least one purchase during the 18-mo period before SCS implantation.
bAt least one purchase during the 18-mo period starting at the 6-mo washout period after SCS implantation.
cP-values were calculated using Fischer's exact test.